a collaboration between teams at the MRC’s National Institute for Medical Research and MRCT’s Drug Discovery Group has produced a breakthrough in understanding how the malaria parasite triggers its release from infected red blood cells. The identification of a parasite enzyme that plays a key role in this process may provide new leads to anti-malarial drug design.
Invalid or expired token..
MRCT will use its proprietary technology and advanced know-how to humanize Intellect’s beta-amyloid specific, monoclonal antibodies for the treatment of Alzheimer’s disease. The antibodies are intended as a form of passive immunization to promote clearance from the brain of the endogenous soluble Alzheimer’s toxin, beta-amyloid, where it accumulates and causes devastating damage to victims of the disease. Humanization is an essential step in making antibodies safe for use in humans.
The collaborative agreement will cover development of a humanised antibody for the treatment of certain forms of cancer. The Therapeutic Antibody Group (TAG) at MRCT will use its proprietary CDR grafting technology to generate a humanised clinical candidate from a murine antibody discovered at Organon’s Research Center in Cambridge, MA,.
SLE is a very important disease area, affecting over 1.5 Million people in the USA without any effective therapies. MRCT will use its proprietary humanization technology to generate the humanized clinical candidate from Ginkgo Biomedical Research Institute's mouse antibody.